MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jmv.70978

Медицинская библиотека · Journal of medical virology · 2026

Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.

Yan Lu, Wubuliaishan Maimaitijiang, Kou Xiaoni, Tuerxun Maimaitiaili, Yang Mingbo, Ji Fanpu, He Yingli, Wang Jiuping, Zhu Longdong, Gao Xiaohong, Jing Fuchun, Ding Xiangchun, Du Hong, Zhang Ye, Jiang Hong

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

To assess the sustained virologic response (SVR12) and safety profile of 12-week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)-infected patients across genotypes in Northwest China. This prospective cohort study (2023-2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis C Prevention Guidelines (2022). Participants received daily oral coblopasvir (60 mg) and sofosbuvir (400 mg) for 12 weeks. Key endpoints included HCV RNA quantification, genotype distribution, liver/kidney biomarkers, ultrasound findings, and liver stiffness measurements at baseline, end-of-treatment (EOT), and 12 weeks post-treatment (SVR12). Cirrhosis was defined by ultrasound and transient elastography (> 14.6 kPa). Of 209 initiators, 170 completed treatment (median age 52.5; 57.1% female), including 21 cirrhotic patients. Genotype distribution showed predominance of 1b (38.2%), 2a (31.2%), and 3a (12.4%), with rare 6a (0.6%) and untypable (2.4%). The EOT virologic clearance rate reached 98.8% (168/170), with SVR12 of 99.4% (128/129). Significant improvements occurred in liver biochemical indicators: ALT (p < 0.001), AST (p < 0.001), GGT (p < 0.001), TBil (p = 0.04 at SVR12). RBC increased (p = 0.04 at EOT; p = 0.00358 at SVR12). No renal impairment was observed (Cr, UA, UREA p > 0.05). The regimen demonstrated excellent tolerability with no severe adverse events. The COB/SOF combination achieved high SVR12 rates (> 99%) across diverse HCV genotypes in Northwest China, including cirrhotic patients, with concurrent liver function recovery and stable renal parameters. These real-world data support its first-line application in resource-limited regions.

Для цитирования: Yan Lu, Wubuliaishan Maimaitijiang, Kou Xiaoni, Tuerxun Maimaitiaili, Yang Mingbo, Ji Fanpu, He Yingli, Wang Jiuping, Zhu Longdong, Gao Xiaohong, Jing Fuchun, Ding Xiangchun, Du Hong, Zhang Ye, Jiang Hong. Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.. Journal of medical virology. 2026. DOI: 10.1002/jmv.70978.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.